Biomarin Pharmaceutical Inc (BMRN)
76.93
+1.42 +1.88%
NASDAQ
May 14, 20:00
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 1.844B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 4.06 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 795.09M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 75.28% |
| Profit Margin (Quarterly) | 3.57% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 14.06B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 7.774 |
| PE Ratio | 18.97 |
| Price to Book Value | 3.382 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.2586 |
| Free Cash Flow (Quarterly) | 85.26M |
| Return on Equity | Upgrade |
View All BMRN News
News
-
WireHeadlineTime (ET)
-
PR Newswire05/12 08:31
-
Yahoo05/10 12:16
-
Yahoo05/04 16:03
-
PR Newswire05/03 08:30
-
Yahoo05/03 04:38
-
MT Newswires04/30 11:15
-
Yahoo04/30 09:58
-
MT Newswires04/30 09:14
-
Yahoo04/30 08:49
-
Yahoo04/29 23:31
-
SA Breaking News04/29 17:49
-
Yahoo04/29 17:25
-
MT Newswires04/29 17:01
-
SA Breaking News04/29 16:10
-
MT Newswires04/29 16:09
-
PR Newswire04/29 16:03
-
Yahoo04/29 14:30
-
MT Newswires04/29 13:28
-
SA Breaking News04/28 08:59
-
PR Newswire04/28 08:31
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 08/04/2021 00:00 | Earnings Results | Q2 2021 Earnings Results |
| 08/04/2021 16:30 | Earnings Calls | Q2 2021 Earnings Call |
| 04/29/2021 00:00 | Earnings Results | Q1 2021 Earnings Results |
| 04/29/2021 16:30 EDT | Earnings Calls | Q1 2021 Earnings Call |
| 02/25/2021 00:00 | Earnings Results | Q4 2020 Earnings Results |
| 02/25/2021 16:30 EST | Earnings Calls | Q4 2020 Earnings Call |
| 11/05/2020 00:00 | Earnings Results | Q3 2020 Earnings Results |
| 11/05/2020 16:30 EST | Earnings Calls | Q3 2020 Earnings Call |
| 08/04/2020 16:30 EDT | Earnings Calls | Q2 2020 Earnings Call |
| 08/04/2020 00:00 | Earnings Results | Q2 2020 Earnings Results |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.
- URL: http://www.bmrn.com
- Investor Relations URL: http://investors.bmrn.com/
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: Aug. 04, 2021
- Last Earnings Release: Apr. 29, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 76.93 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| PBE | Invesco Dynamic Biotech & Genome ETF | 5.24% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.22% |
| BBH | VanEck Vectors Biotech ETF | 2.81% |
| VHCOX | Vanguard Capital Opportunity Inv | 2.19% |
| APSRX | Fiera Capital Small/Mid-Cap Growth Inv | 1.84% |
| FXH | First Trust Health Care AlphaDEX® ETF | 1.80% |
| RYCFX | Rydex Biotechnology C | 1.61% |
| HQH | Tekla Healthcare Investors | 1.51% |
| POGRX | PRIMECAP Odyssey Growth | 1.38% |
| POAGX | PRIMECAP Odyssey Aggressive Growth | 1.32% |
| IBB | iShares Nasdaq Biotechnology ETF | 1.20% |
| CAFFX | American Funds AMCAP 529F1 | 0.93% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- BMRN Tweets Stocktwits
Advertisement
